Innate Pharma (IPH) Aktienübersicht
Innate Pharma S.A. ist ein Biotechnologieunternehmen, das Immuntherapien für Krebspatienten in Frankreich und international entwickelt. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 1/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 0/6 |
| Dividenden | 0/6 |
IPH Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Innate Pharma S.A. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | €1.57 |
| 52-Wochen-Hoch | €2.20 |
| 52-Wochen-Tief | €1.03 |
| Beta | 0.88 |
| 1 Monat Veränderung | 0.77% |
| 3 Monate Veränderung | 31.61% |
| 1 Jahr Veränderung | 4.79% |
| 3 Jahre Veränderung | -45.35% |
| 5 Jahre Veränderung | -42.13% |
| Veränderung seit IPO | -67.41% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jun 26
IPH: 2026 Lung Cancer Trial Data Will Support Higher Future Multiple
Analysts have trimmed their fair value estimate for Innate Pharma from €6.10 to €5.35, citing updated assumptions that combine higher revenue growth expectations with a much lower profit margin outlook and a substantially higher future P/E multiple. What’s in the News for Innate Pharma Innate Pharma plans to present interim results from the Phase 2 MATISSE trial of IPH5201 in combination with durvalumab and platinum-based chemotherapy in resectable non small cell lung cancer at the AACR Annual Meeting 2026 in San Diego, California, during a Clinical Trials Plenary Session.
Narrativ-Update • Jun 04
IPH: 2026 Oncology Readouts Will Drive Reassessment Of Risk Reward Profile
Analysts have adjusted their price target on Innate Pharma to €8, reflecting updated assumptions on discount rates, revenue growth, profit margins and a very large forward P/E multiple, supported by upcoming oncology catalysts highlighted in recent research. What's in the News Interim results from the Phase 2 MATISSE trial of IPH5201 plus durvalumab and platinum-based chemotherapy in resectable non small cell lung cancer are scheduled for a Clinical Trials Plenary Session at the AACR Annual Meeting 2026 in San Diego, California, with abstract code CT231 and session CTPL04, Advances in Immunotherapy, on Tuesday, April 21, 2026, from 10:45 to 11:00 AM PDT.Narrativ-Update • May 11
IPH: 2026 Oncology Catalysts Will Drive Reassessment Of Risk Reward Profile
Analysts have lifted their price target on Innate Pharma to €8, citing a recalibrated risk profile, a slightly lower discount rate and updated expectations around revenue growth, profit margins and future P/E in light of what they describe as a crucial catalyst stretch for the company’s oncology pipeline through 2026. Analyst Commentary Analysts highlight that the updated €8 price target is closely linked to what they describe as a tight catalyst timeline through 2026.Narrativ-Update • Apr 24
IPH: 2026 Oncology Readouts Will Define Upside Potential For This Catalyst Story
Narrative update overview Analysts have maintained a €4.50 price target for Innate Pharma, citing updated assumptions on discount rate, revenue, profit margins and future P/E, alongside upcoming 2026 oncology catalysts highlighted in recent Street research. Analyst Commentary Recent Street research frames Innate Pharma as a high-risk, event driven story into 2026, with attention centered on three oncology programs that analysts see as key to justifying current valuation assumptions.Recent updates
Narrativ-Update • Jun 26
IPH: 2026 Lung Cancer Trial Data Will Support Higher Future Multiple
Analysts have trimmed their fair value estimate for Innate Pharma from €6.10 to €5.35, citing updated assumptions that combine higher revenue growth expectations with a much lower profit margin outlook and a substantially higher future P/E multiple. What’s in the News for Innate Pharma Innate Pharma plans to present interim results from the Phase 2 MATISSE trial of IPH5201 in combination with durvalumab and platinum-based chemotherapy in resectable non small cell lung cancer at the AACR Annual Meeting 2026 in San Diego, California, during a Clinical Trials Plenary Session.Narrativ-Update • Jun 04
IPH: 2026 Oncology Readouts Will Drive Reassessment Of Risk Reward Profile
Analysts have adjusted their price target on Innate Pharma to €8, reflecting updated assumptions on discount rates, revenue growth, profit margins and a very large forward P/E multiple, supported by upcoming oncology catalysts highlighted in recent research. What's in the News Interim results from the Phase 2 MATISSE trial of IPH5201 plus durvalumab and platinum-based chemotherapy in resectable non small cell lung cancer are scheduled for a Clinical Trials Plenary Session at the AACR Annual Meeting 2026 in San Diego, California, with abstract code CT231 and session CTPL04, Advances in Immunotherapy, on Tuesday, April 21, 2026, from 10:45 to 11:00 AM PDT.Narrativ-Update • May 11
IPH: 2026 Oncology Catalysts Will Drive Reassessment Of Risk Reward Profile
Analysts have lifted their price target on Innate Pharma to €8, citing a recalibrated risk profile, a slightly lower discount rate and updated expectations around revenue growth, profit margins and future P/E in light of what they describe as a crucial catalyst stretch for the company’s oncology pipeline through 2026. Analyst Commentary Analysts highlight that the updated €8 price target is closely linked to what they describe as a tight catalyst timeline through 2026.Narrativ-Update • Apr 24
IPH: 2026 Oncology Readouts Will Define Upside Potential For This Catalyst Story
Narrative update overview Analysts have maintained a €4.50 price target for Innate Pharma, citing updated assumptions on discount rate, revenue, profit margins and future P/E, alongside upcoming 2026 oncology catalysts highlighted in recent Street research. Analyst Commentary Recent Street research frames Innate Pharma as a high-risk, event driven story into 2026, with attention centered on three oncology programs that analysts see as key to justifying current valuation assumptions.Narrativ-Update • Apr 09
IPH: Crucial 2026 Oncology Catalysts Are Expected To Unlock Long Term Upside
Analysts have trimmed their fair value estimate for Innate Pharma from about €6.10 to roughly €4.50, citing a reset in revenue growth expectations and a much higher assumed future P/E multiple, while also highlighting upcoming 2026 oncology catalysts as key to the story. Analyst Commentary Recent research has framed 2026 as an important test for Innate Pharma, with several oncology readouts and milestones clustered into what has been described as a crucial catalyst stretch.Analyseartikel • Mar 29
Earnings Update: Innate Pharma S.A. (EPA:IPH) Just Reported And Analysts Are Boosting Their Estimates
Investors in Innate Pharma S.A. ( EPA:IPH ) had a good week, as its shares rose 2.4% to close at €1.10 following the...Narrativ-Update • Mar 25
IPH: 2026 Oncology Catalysts Are Expected To Support Higher Future Multiple
Analysts have raised their price target on Innate Pharma to €8, citing a refreshed view of the company’s 2026 oncology catalyst lineup, including upcoming monalizumab PACIFIC-9 topline data, IPH4502 Phase 1 readout in solid tumors, and potential Phase 3 initiation for lacutamab pending financing. Analyst Commentary Recent commentary frames Innate Pharma as entering what some bullish analysts describe as a crucial catalyst stretch in 2026, with three oncology programs all lined up for key clinical events.Narrativ-Update • Mar 11
IPH: Higher Margin Outlook Will Support Higher Future Earnings Multiple
Analysts have adjusted their price target on Innate Pharma, reflecting updated assumptions for the company’s discount rate, revenue growth outlook and future P/E. The new target is now set at €6.10, compared with the previous €6.10.Narrativ-Update • Feb 25
IPH: Higher Margin Outlook Will Support Significantly Improved Future Earnings Multiple
Analysts have lifted their price target on Innate Pharma from €4.93 to €6.10, citing updated assumptions for revenue, profit margins and future P/E that together support a higher estimated fair value despite a slightly higher discount rate. Valuation Changes Fair Value: analyst estimate raised from €4.93 to €6.10, representing a sizeable upward revision in the implied share value.Narrativ-Update • Feb 11
IPH: Updated Assumptions For Discount Rate Will Support Long Term Upside
Analysts have kept their price target for Innate Pharma broadly in line with prior views, with only a marginal adjustment reflecting updated assumptions on the discount rate, revenue growth and future P/E, rather than any major shift in conviction. Valuation Changes Fair Value: Kept unchanged at €6.10, indicating no alteration to the central valuation estimate.Narrativ-Update • Jan 27
IPH: Upcoming Phase 3 CTCL Trial Will Support Long Term Upside Potential
Analysts have trimmed their price targets for Innate Pharma by a small amount, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower forward P/E, which together indicate a more measured view of the company’s risk and earnings profile. What's in the News The FDA completed its review of Innate Pharma's confirmatory Phase 3 protocol for lacutamab in cutaneous T cell lymphomas, with no further comments, clearing the TELLOMAK 3 trial to proceed (Key Developments).Narrativ-Update • Jan 12
IPH: Regulatory Progress In Cutaneous T-Cell Lymphomas Will Drive Future Upside
Analysts have raised their price target for Innate Pharma, citing a higher fair value estimate of €6.10 per share compared with the prior €2.49. The revised estimate is supported by updated assumptions around revenue growth, profit margins, discount rate and future P/E.Analyseartikel • Nov 17
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Narrativ-Update • Sep 18
Clinical Trial Enrollment And FDA Designation Will Open Oncology Opportunities
Analysts have raised Innate Pharma’s price target to €4.93 amid a refocused pipeline and higher risk concentration on antibody-drug conjugates, while cautioning that execution challenges, financing overhang, and lack of partnerships temper near-term confidence. Analyst Commentary Bearish analysts cite Innate Pharma's decision to deprioritize its proprietary antibody-based NK cell engager platform, which they believe overly concentrates the company’s pipeline risk onto its antibody-drug conjugate strategy.Analyseartikel • Jul 19
Innate Pharma S.A.'s (EPA:IPH) Popularity With Investors Is Under Threat From Overpricing
You may think that with a price-to-sales (or "P/S") ratio of 7.9x Innate Pharma S.A. ( EPA:IPH ) is a stock to avoid...
Neues Narrativ • Apr 04
Clinical Trial Enrollment And FDA Designation Will Open Oncology Opportunities
A robust pipeline of innovative oncology therapeutics and drug candidates highlights strong R&D productivity potentially leading to substantial future earnings.Analyseartikel • Apr 02
News Flash: Analysts Just Made A Notable Upgrade To Their Innate Pharma S.A. (EPA:IPH) Forecasts
Celebrations may be in order for Innate Pharma S.A. ( EPA:IPH ) shareholders, with the analysts delivering a...Analyseartikel • Feb 22
Revenues Not Telling The Story For Innate Pharma S.A. (EPA:IPH) After Shares Rise 26%
Innate Pharma S.A. ( EPA:IPH ) shares have continued their recent momentum with a 26% gain in the last month alone. The...Analyseartikel • Dec 20
Subdued Growth No Barrier To Innate Pharma S.A. (EPA:IPH) With Shares Advancing 37%
Innate Pharma S.A. ( EPA:IPH ) shares have had a really impressive month, gaining 37% after a shaky period beforehand...Analyseartikel • Oct 24
Risks To Shareholder Returns Are Elevated At These Prices For Innate Pharma S.A. (EPA:IPH)
It's not a stretch to say that Innate Pharma S.A.'s ( EPA:IPH ) price-to-sales (or "P/S") ratio of 4.1x right now seems...Analyseartikel • May 21
Benign Growth For Innate Pharma S.A. (EPA:IPH) Underpins Its Share Price
You may think that with a price-to-sales (or "P/S") ratio of 3.4x Innate Pharma S.A. ( EPA:IPH ) is definitely a stock...Analyseartikel • Mar 24
Innate Pharma S.A. (EPA:IPH) Annual Results: Here's What Analysts Are Forecasting For This Year
Innate Pharma S.A. ( EPA:IPH ) just released its latest annual results and things are looking bullish. The results were...Analyseartikel • Dec 21
Is Innate Pharma (EPA:IPH) Using Debt In A Risky Way?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Sep 30
Analysts' Revenue Estimates For Innate Pharma S.A. (EPA:IPH) Are Surging Higher
Innate Pharma S.A. ( EPA:IPH ) shareholders will have a reason to smile today, with the analysts making substantial...Analyseartikel • Sep 16
Some Innate Pharma S.A. (EPA:IPH) Analysts Just Made A Major Cut To Next Year's Estimates
Today is shaping up negative for Innate Pharma S.A. ( EPA:IPH ) shareholders, with the analysts delivering a...Aktionärsrenditen
| IPH | FR Biotechs | FR Markt | |
|---|---|---|---|
| 7D | -5.4% | -8.2% | -1.8% |
| 1Y | 4.8% | 360.1% | 2.0% |
Rendite im Vergleich zur Industrie: IPH unter dem Niveau der Branche French Biotechs , die im vergangenen Jahr eine Rendite von 360.1% erzielte.
Rendite vs. Markt: IPH übertraf den Markt French, der im vergangenen Jahr eine Rendite von 2 erzielte.
Preisvolatilität
| IPH volatility | |
|---|---|
| IPH Average Weekly Movement | 13.2% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in FR Market | 10.8% |
| 10% least volatile stocks in FR Market | 2.5% |
Stabiler Aktienkurs: Der Aktienkurs von IPH war in den letzten 3 Monaten im Vergleich zum French -Markt volatil.
Volatilität im Zeitverlauf: IPHDie wöchentliche Volatilität (13%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der French Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1999 | 164 | Jonathan Dickinson | www.innate-pharma.com |
Innate Pharma S.A. ist ein Biotechnologieunternehmen, das Immuntherapien für Krebspatienten in Frankreich und international entwickelt. Zu den Produkten des Unternehmens gehören Lacutamab (IPH4102), ein Antikörper gegen KIR3DL2, der sich in klinischen Phase-II-Studien zur Behandlung von kutanen T-Zell- und peripheren T-Zell-Lymphomen sowie in klinischen Phase-II-Studien zur Behandlung des refraktären Sézary-Syndroms befindet; Monalizumab, ein Immun-Checkpoint-Inhibitor, der sich in klinischen Phase-III-Studien zur Behandlung fortgeschrittener solider Tumore wie Darm- und Lungenkrebs sowie Kopf- und Halskrebs befindet; IPH5201, ein blockierender Antikörper, der sich in klinischen Studien der Phase II befindet und auf den immunsuppressiven CD39-Signalweg abzielt; IPH5301, ein Anti-CD73-Antikörper, der auf den immunsuppressiven Adenosin-Signalweg abzielt, um die Antitumorimmunität zu fördern; IPH6401, ein auf BCMA abzielender NK-Zell-Engager; und IPH6101, ein auf NKp46 basierender NK-Zell-Engager, der auf CD123 abzielt, proprietäres multispezifisches Antikörperformat; und IPH62, ein auf B7-H3 abzielender NK-Zell-Engager. Seine Produkte in präklinischen Studien sind IPH43, ein Anti-MICA/B ADC und IPH45, ein Antikörper-Wirkstoff-Konjugat (ADC); und IPH67, ein nicht bekannt gegebener, multispezifischer ANKET.
Innate Pharma S.A.'s Grundlagenzusammenfassung
| IPH grundlegende Statistiken | |
|---|---|
| Marktanteil | €147.69m |
| Gewinn(TTM) | -€49.18m |
| Umsatz(TTM) | €9.01m |
16.4x
Kurs-Umsatz-Verhältnis-3.0x
Kurs-Gewinn-Verhältnis Ist IPH zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| IPH Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | €9.01m |
| Kosten der Einnahmen | €43.62m |
| Bruttogewinn | -€34.61m |
| Sonstige Ausgaben | €14.56m |
| Gewinn | -€49.18m |
Zuletzt gemeldete Gewinne
Dec 31, 2025
Datum des nächsten Gewinnberichts
Sep 17, 2026
| Gewinn per Aktie (EPS) | -0.52 |
| Bruttomarge | -384.40% |
| Nettogewinnspanne | -546.11% |
| Schulden/Eigenkapital-Verhältnis | -102.2% |
Wie hat sich IPH auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/12 03:09 |
| Aktienkurs zum Tagesende | 2026/07/10 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Innate Pharma S.A. wird von 13 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Justin Zelin | BTIG |
| Suranjit Mukherjee | BTIG |
| Yigal Nochomovitz | Citigroup Inc |